Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$26.01 USD
+1.72 (7.08%)
Updated May 13, 2024 04:00 PM ET
After-Market: $26.05 +0.04 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Dianthus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 81 | 75 | 79 | 83 |
Income After Depreciation & Amortization | -48 | -81 | -75 | -79 | -83 |
Non-Operating Income | 5 | 4 | 4 | 4 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -44 | -76 | -71 | -75 | -77 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -76 | -71 | -75 | -77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -44 | -76 | -71 | -75 | -77 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -79 | -73 | -77 | -81 |
Depreciation & Amortization (Cash Flow) | -1 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -48 | -81 | -75 | -79 | -83 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.15 | NA | 3.43 | 2.75 | 2.31 |
Diluted EPS Before Non-Recurring Items | -8.45 | NA | -20.64 | -27.36 | -33.12 |
Diluted Net EPS (GAAP) | -8.45 | -20.64 | -20.64 | -27.36 | -33.12 |
Fiscal Year end for Dianthus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.87 | 1.90 | 0.92 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.87 | 1.90 | 0.92 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 18.72 | 14.74 | 16.68 | 7.38 | 32.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.85 | -12.84 | -15.76 | -7.38 | -32.14 |
Non-Operating Income | 4.10 | -3.43 | 1.00 | 4.09 | 2.96 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -13.75 | 3.66 | -14.76 | -3.28 | -29.17 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.75 | 3.66 | -14.76 | -3.28 | -29.17 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -13.75 | 3.66 | -14.76 | -3.28 | -29.17 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 25.67 | 14.82 | 3.91 | 3.79 | NA |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.71 | -3.78 | -0.80 | NA |
Diluted Net EPS (GAAP) | -0.54 | 3.81 | -3.78 | -0.80 | -7.68 |